Trexquant Investment LP Acquires Shares of 68,516 Abeona Therapeutics Inc (NASDAQ:ABEO)

Trexquant Investment LP bought a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 68,516 shares of the biopharmaceutical company's stock, valued at approximately $382,000. Trexquant Investment LP owned approximately 0.16% of Abeona Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABEO. Wellington Management Group LLP bought a new position in shares of Abeona Therapeutics in the 4th quarter valued at $520,000. JPMorgan Chase & Co. raised its position in Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 28,606 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company's stock valued at $2,942,000 after purchasing an additional 83,050 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Abeona Therapeutics during the third quarter worth about $160,000. Finally, Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the third quarter worth about $84,000. Institutional investors own 80.56% of the company's stock.

Wall Street Analyst Weigh In

ABEO has been the topic of several recent research reports. Oppenheimer began coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, March 24th. Finally, StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $17.50.

Abeona Therapeutics Trading Down 0.2 %

Abeona Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $4.84. 822,763 shares of the company's stock were exchanged, compared to its average volume of 449,567. The firm's 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.67. Abeona Therapeutics Inc has a twelve month low of $3.05 and a twelve month high of $7.73. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $236.19 million, a PE ratio of -1.80 and a beta of 1.71.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19. Research analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Insider Transactions at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. This represents a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 33,000 shares of company stock valued at $161,420 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.